Jo.

Problemstillingen med 10 % nedgang per nå i dag er at i går fikk nok ikke alle med seg mandagens kraftige stigningen før børsen stengte. I dag derimot er det nok en rekke aksjonærer som selger for å å lette sin Begenbio-balanse. Det kan også være eiere som i forrige uke kjøpte for 6 kroner. I morges ble det omsatt for over en million kroner der alt gikk for over 8 kroner. Hvilket er bra fortjeneste over en helg - for ovennevnte..

Hva mener du med problemstillingen?. Det er vel ingen problemstilling at aksjen går opp og ned på mandag eller andre dager. Noen taper og noen tjener, er det og en problemstilling.

Spennede innlegg fra profil «369» i Forum Shareville

I denne ferske artikkelen fra 14. november, fremheves bemcentinib som potensielt ledende i å hemme vekst av Xoo. Xoo er en bakteriell patovar som forårsaker alvorlig skade på ris, annet gress og planter (https://en.wikipedia.org/wiki/Xanthomonas_oryzae_pv._oryzae). Med andre ord kan bemcentinib potensielt bidra til mer mat i verden. I artikkelen så kaller de bemcentinib for DB12411: https://www.mdpi.com/1422-0067/25/22/12236

Fra abstrakt: "Virtual screening based on the target identified DB12411 as a lead compound with the potential for new antibacterial agents."

Lenger ned i artikkelen: "As a comparison, the commercial agent bismerthiazol has been reported in multiple studies to have an MIC range of 0.14 mM to 0.65 mM against Xoo [50,51]. In contrast, DB12411 exhibits a significantly lower MIC than bismerthiazol, indicating stronger antibacterial potential. DB12411, also known as bemcentinib, has been used for treating non-small cell lung cancer, breast cancer, and COVID-19. To date, no report on its antibacterial effect is available. The above experimental results demonstrated that DB12411 could inhibit the growth of Xoo, thus making it a potential lead compound for anti-Xoo agents."


Konklusjon lengst ned i artikkelen :

4. Conclusions

BB caused by Xoo is one of the most serious rice diseases worldwide. In this study, to explore the possible anti-Xoo mechanism of bismerthiazol and identify the new antibacterial target against Xoo, the transcriptomic data from before and after bismerthiazol treatment were integrated into the GSMM to reconstruct a context-specific GSMM of Xoo and simulate the metabolic processes, identifying reactions with significant flux differences. The mechanisms related to the reactions with the large metabolic flux change were in agreement with previous reports, which confirmed the effectiveness of our integration method. Combining literature reports, the study identified the potential target Xoo-GSR, which exhibited metabolic flux change, and its effectiveness was further verified through antibacterial experiments. Virtual screenings were performed based on the Xoo-GSR target through molecular docking, and compound DB12411 (with a MIC of 0.032 mM against Xoo) was screened and verified as an anti-Xoo lead compound. Our results will provide a reference for revealing the antibacterial mechanism of other drugs and identifying more novel drug targets.
Genomic and transcriptomic data are widely used to identify new targets in pathogenic bacteria. However, relying solely on genomic and transcriptomic data has limitations in characterizing Xoo’s metabolic and pharmacological mechanisms, as these data are further removed from actual metabolic activities and may miss critical regulatory details. Although metabolomics methods can directly reflect changes at the metabolite level, the technology remains immature, costly, and limited in precision [55]. The integration of transcriptomic data with a GSMM used in this study is a widely applied and validated analytical approach, serving as an effective alternative to metabolomics to some extent. Integrating metabolic networks with transcriptomic data not only compensates for the limitations of transcriptomics but also provides a feasible and effective alternative for studying metabolic changes [56]. Additionally, to more accurately detect the metabolic changes in Xoo under bismerthiazol treatment, proteomics and metabolomics could also be employed; however, these methods typically require new experimental data, which involves considerable time and resources. Given the current data, combining transcriptomic data with GSMM would be the optimal approach to detect metabolic changes in Xoo.
Although this study primarily focused on GSR as the main research target, our analysis also revealed significant changes in the metabolic flux of several other reactions. Notably, the cytochrome oxidases CYTBD and CYTBO3_4pp exhibited the greatest changes in flux, indicating their crucial roles in the respiratory chain function and oxidative stress management of Xoo. The activity changes in these enzymes directly affect the bacterial energy metabolism and viability, making them potential targets against Xoo. Future research should explore whether CYTBD and CYTBO3_4pp could serve as new strategies against Xanthomonas oryzae pv. oryzae (Xoo) infection. This exploration should include systematic functional validation of these targets through gene knockout and overexpression experiments, as well as extensive in vivo tests to verify the efficacy and safety of potential drug candidates. By thoroughly understanding the roles of these targets in Xoo infections, we can lay a solid scientific foundation for developing new antibiotic strategies.

Hei.
Hva er potensial/sammenhengen her mellom mennesker og planter. Undrende. Tidligere
investor i denne aksjen.
Mvh gammel pensjonist

Snart kjøper kinesiske investorer i horder …

Kan se ut til at vi har fått en ny trend her nå, positivt, uten tvil. Selv om jeg skulle snitte meg ned på 5 kr.
Uansett, vi får se, mulig en skikkelig reprising nå står for tur.
Mulig ekstrem nyttårsrakett dette her, speielt om vi får positive resultater. Om ting går veien blir nok denne en av vinnerne i 2025 kursmessig.

En dobling før vi ser 2025 er vel heller ikke usannsynlig fra dagens nivå, og kan forsåvidt også forsvares.

Gg

Virker som at noen akkumulerer sakte nå for å ikke få opp kursen for mye.